2-chloro-6-(4-chlorophenoxy)pyridine | 174134-67-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-chloro-6-(4-chlorophenoxy)pyridine
• CAS: 174134-67-9
• 化学式: C₁₁H₇Cl₂NO
• 分子量: 240.089
• InChiKey: AQNXHEDDEVEWOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,6-二氯吡啶 、 对氯苯酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 2-chloro-6-(4-chlorophenoxy)pyridine
  参考文献：
  名称：

  [EN] N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  [FR] DÉRIVÉS N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE

  摘要：

  本处描述的是公式I的化合物，制造此类化合物的方法，包含此类化合物的药物组合物和药品，以及用于治疗或预防与葡萄糖苷鞘氨醇合酶（GCS）相关疾病的I化合物。

  公开号：

  WO2015065937A1

文献信息

• COMPOUND HAVING 6-MEMBERED AROMATIC RING
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2253618A1

  公开（公告）日：2010-11-24

  An object of the present invention is to provide an agent for preventing or treating schizophrenia or the like, wherein the compound of the present invention has GPR52 agonist activity. [Means] A compound represented by the following formula (I) or salt thereof: wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, or the like, X1, X2, X3, and X4 represent the same or different -CRx=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or NRy-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, and which may be condensed with an optionally substituted five-to six-membered ring, and Ra, Rb, Rx, and Ry represent the same or different hydrogen atom, halogen atoms, or the like].

  本发明的一个目的是提供一种用于预防或治疗精神分裂症或类似疾病的药剂，其中本发明的化合物具有GPR52激动剂活性。[意味着]由以下式(I)表示的化合物或其盐：其中A代表-(CH2)n-CO-NRa-（n为0到3的整数）或-NRa-CO-，B代表氢原子，卤素原子，氰基，羟基等，X1，X2，X3和X4代表相同或不同的-CRx=或-N=，Y代表-O-，-S-，-S(O)-，-S(O)2-，或NRy-，Z代表键，亚甲基，或乙烯基，Ar1代表一个五至十元芳香环（除噻唑外），可以用一个或多个卤素原子、可选择的卤代C1-6烷基等取代基取代，Ar2代表一个五至六元芳香环，可以用一个或多个卤素原子、可选择的卤代C1-6烷基等取代基取代，可以与一个可选择的取代的五至六元环螯合，并且Ra、Rb、Rx和Ry代表相同或不同的氢原子、卤素原子等。
• Substituent Effects of 2-Pyridones on Selective O-Arylation with Diaryliodonium Salts: Synthesis of 2-Aryloxypyridines under Transition­-Metal-Free Conditions
  作者：Dong-Liang Mo、Xiao-Hua Li、Ai-Hui Ye、Cui Liang

  DOI：10.1055/s-0036-1591884

  日期：2018.4

  An efficient transition-metal-free strategy to synthesize 2-aryloxypyridine derivatives has been developed by a selective O-arylation of 2-pyridones with diaryliodonium salts. The reaction was compatible with a series of functional groups for 2-pyridones and diaryliodonium salts such as halides, nitro, cyano, and ester groups. The substituents at the C6-position of 2-pyridones favored O-arylation products because of steric hindrance. The reaction was easily performed on a gram-scale and 6-chloro-2-pyridone was a good precursor to access various unsubstituted 2-aryloxypyridines by dehalogenation. A P2Y1 lead compound analogue could be prepared in good yield over two steps.

  开发了一种高效的过渡金属自由策略，通过选择性的氧芳基化2-吡啶酮与二芳基碘盐合成2-芳氧基吡啶衍生物。该反应与一系列功能团对2-吡啶酮和二芳基碘盐兼容，如卤素、硝基、氰基和酯基等。2-吡啶酮的C6位取代基有利于氧芳基化产物的生成，因为存在立体位阻。该反应易于在克级规模上进行，并且6-氯-2-吡啶酮是通过去卤代法获得各种未取代的2-芳氧基吡啶的良好前体。通过两步反应可以以较高产率制备P2Y1前体类似物。
• N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US10239832B2

  公开（公告）日：2019-03-26

  Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

  本文描述了式 I 化合物、制造此类化合物的方法、含有此类化合物的药物组合物和药物，以及用于治疗或预防与葡萄糖酰胺合成酶 (GCS) 相关的疾病或病症的式 I 化合物。
• N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  申请人：BioMarin Pharmaceutical Inc.

  公开号：EP3063141B1

  公开（公告）日：2018-02-28
• [EN] N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
  申请人：BIOMARIN PHARM INC

  公开号：WO2015065937A1

  公开（公告）日：2015-05-07

  Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

  本处描述的是公式I的化合物，制造此类化合物的方法，包含此类化合物的药物组合物和药品，以及用于治疗或预防与葡萄糖苷鞘氨醇合酶（GCS）相关疾病的I化合物。